1. Clinical & Scientific Overview
Polyvalent Anti-Snake Venom (Indian 'Big Four' Lyophilised ASV) (TIP-MED-000266, Reference Code [12.34]) is classified under
Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Equine Hyperimmune F(ab')2 Immunoglobulin Antivenom against India's 'Big Four' Venomous Snakes.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.34], p. 171): Bharat Serums ASV, Vins Bioproducts ASV, Haffkine ASV, Premium Serums ASV — Strengths & Dosage Forms: Lyophilised Powder for Injection with 10 mL Sterile Water for Injection (WFI) ampoule (or Liquid ASV 10 mL vial).
Lyophilised Powder for Injection with 10 mL Sterile Water for Injection (WFI) ampoule (or Liquid ASV 10 mL vial).
3. Mechanism of Action & Pharmacodynamics
Lyophilised or liquid equine F(ab')2 antibody fragments bind circulating free venom toxins in plasma and interstitial fluid -> neutralises procoagulant/haemotoxic metalloproteinases (Vipers) and pre-/post-synaptic neurotoxins (Krait/Cobra). Each 10 mL reconstituted vial neutralises at least: 6 mg Cobra, 6 mg Russell's Viper, 4.5 mg Krait, and 4.5 mg Saw-Scaled Viper venom.
4. Therapeutic Indications & Evidence-Supported Uses
- Systemic envenomation by any of the Indian 'Big Four' venomous snakes: (1) Spectacled Cobra (Naja naja), (2) Common Krait (Bungarus caeruleus), (3) Russell's Viper (Daboia russelii), and (4) Saw-Scaled Viper (Echis carinatus)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Ministry of Health & Family Welfare (MoHFW) National Snakebite Protocol: Administer ONLY when signs of systemic envenomation or rapid local progression exist. Initial Dose: 8–10 vials (80–100 mL) diluted in 250–500 mL 0.9% NaCl or 5% Dextrose infused IV over 1 hour (start slowly at 2 mL/min for first 15 min while observing for anaphylaxis). Neurotoxic (Cobra/Krait): If no improvement at 1–2 hours, repeat 10 vials (Max 20 vials total; give Neostigmine + Atropine for postsynaptic Cobra bite). Haemotoxic (Viper): Repeat 20-minute Whole Blood Clotting Test (20WBCT) every 6 hours and give 5–10 vials q6h until blood clots (up to 30 vials). • Paediatric: IDENTICAL TO ADULT DOSE (8–10 vials initial dose)! Snakes inject the same amount of venom into a child as into an adult—NEVER reduce ASV dose by child body weight (dilute in smaller fluid volume of 200 mL to avoid fluid overload).
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.
Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.
Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: No absolute contraindications in systemic snakebite envenomation! DO NOT perform intradermal or conjunctival ASV sensitivity skin tests (MoHFW guidelines state skin tests have zero predictive value for non-IgE anaphylactoid reactions and dangerously delay life-saving therapy). • Precautions: Early anaphylactoid/pyrogenic reactions occur in 20–50% of patients within 10–60 minutes: keep ADRENALINE (1:1000, 0.5 mg IM into anterolateral thigh) drawn up in a syringe at the bedside before starting ASV! If a reaction occurs, temporarily stop ASV, give IM Adrenaline + IV Chlorpheniramine + IV Hydrocortisone, and restart ASV slowly once BP/bronchospasm stabilises.
Key Clinical Precautions: Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.
8. Adverse Effects Profile
- Early anaphylactoid reaction (urticaria, pruritus, rigor/chills, fever, nausea, tachycardia), late serum sickness (fever, arthralgia, lymphadenopathy 5–14 days later).
- Severe bronchospasm, angioedema, hypotensive anaphylactic shock.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Combine with Neostigmine (1
- 5 mg IV/IM + Atropine 0
- 6 mg) in neurotoxic Cobra bites (postsynaptic alpha-neurotoxin); pre-synaptic Krait beta-bungarotoxin responds poorly to Neostigmine and requires early mechanical ventilation
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Reassure patient/family that pressure-immobilisation, tourniquets, incision, suction, or herbal stones must be avoided; report delayed fever or joint pain 1-2 weeks after discharge (serum sickness).
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / MoHFW National Snakebite Treatment Protocol
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.34] (p. 171)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.31] Naloxone Hydrochloride (Parenteral Opioid Overdose Antidote) — Pure Competitive Opioid Receptor Antagonist (Mu, Kappa & Delta An
- [12.32] Atropine Sulphate (Parenteral Bradycardia & OP Poisoning Antidote) — Competitive Muscarinic Acetylcholine Receptor Antagonist (Anticho
- [12.33] Pralidoxime Chloride / Iodide (2-PAM Cholinesterase Reactivator) — Cholinesterase Reactivator Oxime Antidote (Organophosphate Antido
- [12.35] Rabies Vaccine (ID/IM Cell-Culture) & Rabies Immunoglobulin (RIG) — Inactivated Cell-Culture Rabies Vaccine (Active Immunisation) & P
